Advisory Alpha LLC Reduces Holdings in Agilent Technologies, Inc. $A

Advisory Alpha LLC lessened its position in shares of Agilent Technologies, Inc. (NYSE:A) by 4.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,913 shares of the medical research company’s stock after selling 136 shares during the period. Advisory Alpha LLC’s holdings in Agilent Technologies were worth $344,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock valued at $4,279,000 after buying an additional 4,362 shares during the last quarter. Alps Advisors Inc. raised its stake in shares of Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock valued at $1,563,000 after purchasing an additional 3,040 shares during the period. TrueMark Investments LLC bought a new stake in shares of Agilent Technologies during the 2nd quarter valued at $1,999,000. Fenimore Asset Management Inc raised its stake in shares of Agilent Technologies by 2.7% during the 2nd quarter. Fenimore Asset Management Inc now owns 180,880 shares of the medical research company’s stock valued at $21,346,000 after purchasing an additional 4,823 shares during the period. Finally, D.A. Davidson & CO. raised its stake in shares of Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock valued at $1,108,000 after purchasing an additional 2,207 shares during the period.

Agilent Technologies Price Performance

Shares of NYSE A opened at $143.15 on Thursday. The firm has a market capitalization of $40.58 billion, a P/E ratio of 33.60, a P/E/G ratio of 4.76 and a beta of 1.26. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The stock’s 50-day simple moving average is $131.95 and its two-hundred day simple moving average is $120.31. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th were issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Tuesday, September 30th. Agilent Technologies’s dividend payout ratio is presently 23.24%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. TD Cowen boosted their price objective on Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Robert W. Baird boosted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Rothschild & Co Redburn assumed coverage on Agilent Technologies in a research note on Wednesday, October 8th. They set a “buy” rating and a $165.00 price objective on the stock. UBS Group upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $130.00 to $170.00 in a research note on Wednesday, October 8th. Finally, Evercore ISI boosted their price objective on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.